Most Active Stocks After Hours on August 18, 2025: VCIT, TWLO, STR, NVDA, OPEN, BAC, JNJ, NEOG, PANW, VNOM, KVUE, CNH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 After Hours Performance: The NASDAQ 100 is down -2.43 to 23,711.33 with a total after-hours volume of 129,178,808 shares traded.
Active Stocks Overview: Notable active stocks include Vanguard Intermediate-Term Corporate Bond ETF (VCIT) unchanged at $82.96, Twilio Inc. (TWLO) up +0.45 at $105.50, and Sitio Royalties Corp. (STR) down -0.04 at $18.08.
Stock Recommendations: Several stocks such as TWLO, NVIDIA Corporation (NVDA), and Bank of America Corporation (BAC) are reported to be in the "buy range" according to Zacks recommendations.
Earnings Forecast Updates: Companies like Bank of America and Johnson & Johnson have had multiple upward revisions for their earnings forecasts for the fiscal quarter ending December 2025.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 219.570
Low
176.00
Averages
207.26
High
230.00
Current: 219.570
Low
176.00
Averages
207.26
High
230.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
